Implantable medical device comprising copolymer of L-lactide with improved fracture toughness

• US 8,119,704 B2
• Filed: 07/21/2009
• Issued: 02/21/2012
• Est. Priority Date: 07/21/2009
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories)
• Inventors: Wang, Yunbing, Oberhauser, James, Gada, Manish, Glauser, Thierry, Gueriguian, Vincent, Steichen, Bethany, Kleiner, Lothar, Ma, Xiao
• Primary Examiner(s): Yoon, Tae H
• Application Number:
  US12/506,881
• Publication Number:
  US 20110022163A1
• Time in Patent Office: 945 Days
• Field of Search: 523/113, 528/354, 264/235, 623/1.38, 623/1.49
• US Class Current: 523/113
• CPC Class Codes: A61L 31/06 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds A61L31/041 takes precedence
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

The present invention relates to implantable medical devices comprising a L-lactide-constitutional unit-containing copolymer having a wt % percent crystallinity of 40% or less.

Claims

1. An implantable medical device, comprising:

a copolymer comprising;

L-lactide and from about 4 mol % to about 5 mol % glycolide, wherein the copolymer has a crystallinity from about 20 wt % to about 30 wt % prior to fabrication into the device;

the copolymer being blended with about 2 wt % to about 10 wt % poly(D-lactide-co-glycolide) based on the total weight of copolymer plus poly(D-lactide-co-glycolide) wherein the poly(D-lactide-co-glycolide) comprises about 2 mol % to about 10 mol % glycolide monomer.

2. The implantable medical device of claim 1, comprising a stent.

3. An implantable medical device, comprising:

a copolymer comprising;

L-lactide and from about 1 mol % to about 10 mol % ε

-caprolactone, wherein the copolymer has a crystallinity from about 20 wt % to about 30 wt % prior to fabrication into the device;

the copolymer being blended with about 2 wt % to about 10 wt % poly(D-lactide-co-ε

-caprolactone) based on the total weight of copolymer plus poly(D-lactide-co-ε

-caprolactone) wherein the poly(D-lactide-co-ε

-caprolactone) comprises about 2 mol % to about 10 mol % ε

-caprolactone monomer.

4. The implantable medical device of claim 3, comprising a stent.

5. An implantable medical device, comprising:

a copolymer comprising;

L-lactide and from about 1 mol % to about 10 mol % dioxanone, wherein the copolymer has a crystallinity from about 20 wt % to about 30 wt % prior to fabrication into the device;

the copolymer being blended with about 2 wt % to about 10 wt % poly(D-lactide-co-dioxanone) based on the total weight of copolymer plus poly(D-lactide-co-dioxanone) wherein the poly(D-lactide-co-dioxanone) comprises about 2 mol % to about 10 mol % dioxanone monomer.

6. The implantable medical device of claim 5, comprising a stent.